XGN Stock Overview
Develops and commercializes various testing products under the AVISE brand in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Exagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.30 |
| Beta | 1.35 |
| 11 Month Change | 50.00% |
| 3 Month Change | 37.70% |
| 1 Year Change | 169.23% |
| 33 Year Change | -64.44% |
| 5 Year Change | -75.31% |
| Change since IPO | -77.40% |
Recent News & Updates
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Recent updates
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
Jul 13Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
May 21Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price
Apr 07Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Mar 03Exagen issues preliminary testing revenue ahead of ICT chat
Jan 11Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?
Jan 05Exagen (XGN) Investor Presentation - Slideshow
Nov 20Shareholder Returns
| XGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 52.7% | -6.5% | -1.0% |
| 1Y | 169.2% | 14.6% | 30.3% |
Return vs Industry: XGN exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: XGN exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 177 | John Aballi | www.exagen.com |
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
Exagen Inc. Fundamentals Summary
| XGN fundamental statistics | |
|---|---|
| Market cap | US$61.37m |
| Earnings (TTM) | -US$16.93m |
| Revenue (TTM) | US$55.75m |
1.3x
P/S Ratio-4.3x
P/E RatioIs XGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XGN income statement (TTM) | |
|---|---|
| Revenue | US$55.75m |
| Cost of Revenue | US$22.97m |
| Gross Profit | US$32.78m |
| Other Expenses | US$49.71m |
| Earnings | -US$16.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 58.80% |
| Net Profit Margin | -30.36% |
| Debt/Equity Ratio | 157.4% |
How did XGN perform over the long term?
See historical performance and comparison